A biotechnology company announced Wednesday it has landed a massive financing agreement worth as much as $1.3 billion to help bring a new eczema treatment to market.
Apogee Therapeutics revealed the partnership with Blackstone Life Sciences will fund advanced development and possible commercialization of zumilokibart, an experimental medication for treating eczema. However, company stock prices dropped nearly 12% in early trading following the announcement.
The financing package combines up to $800 million through a royalty arrangement with access to as much as $500 million in senior debt funding.
Zumilokibart represents Apogee’s primary drug candidate and targets moderate-to-severe atopic dermatitis, a persistent skin condition that causes inflammation and irritation.
The company simultaneously released findings from a mid-stage clinical trial involving 346 adult participants. Results showed the experimental treatment successfully met both primary and secondary study objectives.
Trial data revealed that 65.9% of patients receiving the medium dosage and 61.6% of those getting the higher dose experienced at least a 75% reduction in eczema severity after 16 weeks of treatment. By comparison, only 23.4% of participants taking a placebo showed similar improvement.
Citi analyst Geoff Meacham noted that the weaker performance of the high dose compared to the medium dose created somewhat mixed results that could negatively impact stock performance.
Truist analyst Danielle Brill suggested the stock decline might also stem from the royalty deal with Blackstone, which effectively eliminates Apogee as a potential merger and acquisition target.
Company officials plan to move forward with the medium dose formulation into late-stage clinical studies during the latter half of 2026.
Mizuho analyst Joseph Catanzaro praised the medium-dose findings, saying the results combined with less frequent maintenance dosing requirements demonstrate the drug’s potential to become best-in-class for both effectiveness and patient convenience.
Should zumilokibart receive FDA approval, Apogee would gain access to an additional $400 million in royalty funding.
“This is the largest royalty financing for a pre-Phase 3 program to date,” said Kiran Reddy, senior managing director at Blackstone Life Sciences.
